Wainzua had been previously approved for use by patients with ATTRv-PN in the United States, under the brand name Wainua.

AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with ...

(Alliance News) - AstraZeneca PLC on Monday said its Wainzua treatment has been been recommended for EU approval to treat ...

Hereditary transthyretin amyloidosis with polyneuropathy (damage to your peripheral nerves), (hATTR-PN), is a rare disease ...

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

A rabbit sensitized with myelin lipid galactocerebroside develops autoimmune demyelinating polyneuropathy. The nerve conduction study was performed prior to sensitization (a) and at the peak of ...

Ionis has five FDA-approved drugs and promising upcoming approvals. See more about IONS stock and why it warrants a Buy ...

Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty ...

UK MHRA grants marketing authorisation to AstraZeneca’s eplontersen to treat adults with rare inherited nerve disease or polyneuropathy: United Kingdom Friday, October 18, 2024, ...

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.

He's one of our greatest swimmers,, but Michael Klim is facing a new challenge post career.  In 2020 the legendary swimmer ...